Maxigen Biotech Valuation

Q: What is the Fair Price of 1783 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

1783 (NT$44) is trading below our estimate of [[fair value]] (NT$80.03)

Is 1783 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1783 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1783 (NT$44) is trading below our estimate of fair value (NT$80.03)

Significantly Below Fair Value: 1783 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1783?

Key metric: As 1783 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 1783. This is calculated by dividing 1783's market cap by their current earnings.
What is 1783's PE Ratio?
PE Ratio	25.2x
Earnings	NT$155.34m
Market Cap	NT$3.92b

1783 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5.4x
Enterprise Value/EBITDA	19.2x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 1783's PE Ratio compare to its peers?

The above table shows the PE ratio for 1783 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	74x
4169 TCM Biotech International	176.5x	n/a	NT$3.5b
4160 Genetics Generation Advancement	38.7x	n/a	NT$2.3b
1780 Allied Biotech	15.5x	n/a	NT$1.6b
4186 Taiwan Advance Bio-Pharmaceutical	65.4x	n/a	NT$1.4b
1783 Maxigen Biotech	25.2x	n/a	NT$3.9b

Price-To-Earnings vs Peers: 1783 is good value based on its Price-To-Earnings Ratio (25.2x) compared to the peer average (74x).

Price to Earnings Ratio vs Industry

How does 1783's PE Ratio compare vs other companies in the Asian Biotechs Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 1783 is good value based on its Price-To-Earnings Ratio (25.2x) compared to the Asian Biotechs industry average (30.8x).

Price to Earnings Ratio vs Fair Ratio

What is 1783's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1783 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	25.2x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 1783's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

YungShin Global Holding

NT$15.4b

Through its subsidiaries, invests in, manufactures, and sells medicines, animal drugs, agricultural chemicals, industrial medicines, and cosmetics in Taiwan, Mainland China, Japan, and the United States.

3705

NT$57.90

8.2%

27.1%

Winston Medical Supply

NT$1.6b

Winston Medical Supply Co.,Ltd. develops, manufactures, and distributes pharmaceuticals, nutrition supplements, and cosmeceutical products.

6817

NT$88.30

-1.6%

-13.4%

RBC Bioscience

NT$254.3m

Researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia.

6848

NT$19.60

-0.5%

29.8%